| Line | Label | Object Class | Period Type | Balance | Report ElementName |
|---|---|---|---|---|---|
| 1 | Health Care - Biotechnology & Pharmaceuticals (HC-BP) | Network | http://www.sasb.org/xbrl/taxonomy/industry/BiotechnologyAndPharmaceuticals | ||
| 2 | Biotechnology And Pharmaceuticals Industry [Abstract] | Abstract | sasb:BiotechnologyAndPharmaceuticalsIndustryAbstract | ||
| 3 | Biotechnology And Pharmaceuticals Industry, Accounting Metrics [Abstract] | Abstract | sasb:BiotechnologyAndPharmaceuticalsIndustryAccountingMetricsAbstract | ||
| 4 | Safety of Clinical Trial Participants Disclosure [Abstract] | Abstract | sasb:SafetyOfClinicalTrialParticipantsDisclosureAbstract | ||
| 5 | Safety of Clinical Trial Participants Disclosure [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:SafetyOfClinicalTrialParticipantsDisclosureTextBlock | |
| 6 | HC-BP-210a.1 [Abstract] | Abstract | sasb:HCBP210a1Abstract | ||
| 7 | Management Process For Ensuring Quality And Patient Safety During Clinical Trials [Text Block] [Table] | Hypercube | sasb:ManagementProcessForEnsuringQualityAndPatientSafetyDuringClinicalTrialsTextBlockTable | ||
| 8 | Geographical [Axis] | Dimension | srt:StatementGeographicalAxis | ||
| 9 | Geographical [Domain] | Member | srt:SegmentGeographicalDomain | ||
| 10 | Africa [Member] | Member | srt:AfricaMember | ||
| 11 | Americas [Member] | Member | srt:AmericasMember | ||
| 12 | Asia [Member] | Member | srt:AsiaMember | ||
| 13 | Asia Pacific [Member] | Member | srt:AsiaPacificMember | ||
| 14 | Central America [Member] | Member | srt:CentralAmericaMember | ||
| 15 | Europe [Member] | Member | srt:EuropeMember | ||
| 16 | Latin America [Member] | Member | srt:LatinAmericaMember | ||
| 17 | North America [Member] | Member | srt:NorthAmericaMember | ||
| 18 | South America [Member] | Member | srt:SouthAmericaMember | ||
| 19 | UNITED STATES | Abstract | country:US | ||
| 20 | Management Process For Ensuring Quality And Patient Safety During Clinical Trials [Text Block] [Line Items] | LineItems | sasb:ManagementProcessForEnsuringQualityAndPatientSafetyDuringClinicalTrialsTextBlockLineItems | ||
| 21 | Management Process For Ensuring Quality And Patient Safety During Clinical Trials [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:ManagementProcessForEnsuringQualityAndPatientSafetyDuringClinicalTrialsTextBlock | |
| 22 | Processes For Obtaining Informed Consent, Of Incentives Offered To Participants, And Of Any Clinical Trials Terminated Due To Failure To Follow Good Clinical Practice Standards [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:ProcessesForObtainingInformedConsentOfIncentivesOfferedToParticipantsAndOfAnyClinicalTrialsTerminatedDueToFailureToFollowGoodClinicalPracticeStandardsTextBlock | |
| 23 | HC-BP-210a.2 [Abstract] | Abstract | sasb:HCBP210a2Abstract | ||
| 24 | FDA Inspections Related To Clinical Trial Management And Pharmacovigilance [Table] | Hypercube | sasb:FDAInspectionsRelatedToClinicalTrialManagementAndPharmacovigilanceTable | ||
| 25 | FDA Inspection Classification [Axis] | Dimension | sasb:FDAInspectionClassificationAxis | ||
| 26 | FDA Inspection Classification [Domain] | Abstract | sasb:FDAInspectionClassificationDomain | ||
| 27 | Official Action Indicated (OAI) [Member] | Abstract | sasb:OfficialActionIndicatedOAIMember | ||
| 28 | Voluntary Action Indicated (VAI) [Member] | Abstract | sasb:VoluntaryActionIndicatedVAIMember | ||
| 29 | FDA Inspections Related To Clinical Trial Management And Pharmacovigilance [Line Items] | LineItems | sasb:FDAInspectionsRelatedToClinicalTrialManagementAndPharmacovigilanceLineItems | ||
| 30 | FDA Inspections Related To Clinical Trial Management And Pharmacovigilance | Concept (xbrli:nonNegativeIntegerItemType) | For Period | sasb:FDAInspectionsRelatedToClinicalTrialManagementAndPharmacovigilance | |
| 31 | HC-BP-210a.3 [Abstract] | Abstract | sasb:HCBP210a3Abstract | ||
| 32 | Losses As Result Of Legal Proceedings [Table] | Hypercube | sasb:LossesAsResultOfLegalProceedingsTable | ||
| 33 | Legal Proceeding Association [Axis] | Dimension | sasb:LegalProceedingAssociationAxis | ||
| 34 | Legal Proceeding Association [Domain] | Abstract | sasb:LegalProceedingAssociationDomain | ||
| 35 | Bribery Or Corruption [Member] | Abstract | sasb:BriberyOrCorruptionMember | ||
| 36 | Clinical Trials In Developing Countries [Member] | Abstract | sasb:ClinicalTrialsInDevelopingCountriesMember | ||
| 37 | False Marketing Claims [Member] | Abstract | sasb:FalseMarketingClaimsMember | ||
| 38 | Losses As Result Of Legal Proceedings [Line Items] | LineItems | sasb:LossesAsResultOfLegalProceedingsLineItems | ||
| 39 | Losses As Result Of Legal Proceedings | Concept (Monetary) | For Period | sasb:LossesAsResultOfLegalProceedings | |
| 40 | Nature, Context, And Corrective Actions Taken As Result Of Monetary Losses From Legal Proceedings [Text Block] [Table] | Hypercube | sasb:NatureContextAndCorrectiveActionsTakenAsResultOfMonetaryLossesFromLegalProceedingsTextBlockTable | ||
| 41 | Legal Proceeding Association [Axis] | Dimension | sasb:LegalProceedingAssociationAxis | ||
| 42 | Legal Proceeding Association [Domain] | Abstract | sasb:LegalProceedingAssociationDomain | ||
| 43 | Bribery Or Corruption [Member] | Abstract | sasb:BriberyOrCorruptionMember | ||
| 44 | Clinical Trials In Developing Countries [Member] | Abstract | sasb:ClinicalTrialsInDevelopingCountriesMember | ||
| 45 | False Marketing Claims [Member] | Abstract | sasb:FalseMarketingClaimsMember | ||
| 46 | Nature, Context, And Corrective Actions Taken As Result Of Monetary Losses From Legal Proceedings [Text Block] [Line Items] | LineItems | sasb:NatureContextAndCorrectiveActionsTakenAsResultOfMonetaryLossesFromLegalProceedingsTextBlockLineItems | ||
| 47 | Nature, Context, And Corrective Actions Taken As Result Of Monetary Losses From Legal Proceedings [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:NatureContextAndCorrectiveActionsTakenAsResultOfMonetaryLossesFromLegalProceedingsTextBlock | |
| 48 | Access to Medicines Disclosure [Abstract] | Abstract | sasb:AccessToMedicinesDisclosureAbstract | ||
| 49 | Access to Medicines Disclosure [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:AccessToMedicinesDisclosureTextBlock | |
| 50 | HC-BP-240a.1 [Abstract] | Abstract | sasb:HCBP240a1Abstract | ||
| 51 | Actions And Initiatives To Promote Access To Health Care Products For Priority Diseases And In Priority Countries As Defined By Access To Medicine Index [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:ActionsAndInitiativesToPromoteAccessToHealthCareProductsForPriorityDiseasesAndInPriorityCountriesAsDefinedByAccessToMedicineIndexTextBlock | |
| 52 | HC-BP-240a.2 [Abstract] | Abstract | sasb:HCBP240a2Abstract | ||
| 53 | Products Listed On World Health Organization List Of Prequalified Medicinal Products [Table] | Hypercube | sasb:ProductsListedOnWorldHealthOrganizationListOfPrequalifiedMedicinalProductsTable | ||
| 54 | Medical Products [Axis] | Dimension | sasb:MedicalProductsAxis | ||
| 55 | Medical Products [Domain] | Abstract | sasb:MedicalProductsDomain | ||
| 56 | Products Listed On World Health Organization List Of Prequalified Medicinal Products [Line Items] | LineItems | sasb:ProductsListedOnWorldHealthOrganizationListOfPrequalifiedMedicinalProductsLineItems | ||
| 57 | Products Listed On World Health Organization List Of Prequalified Medicinal Products | Concept (enum2:enumerationSetItemType) | For Period | sasb:ProductsListedOnWorldHealthOrganizationListOfPrequalifiedMedicinalProducts | |
| 58 | Affordability And Pricing Disclosure [Abstract] | Abstract | sasb:AffordabilityAndPricingDisclosureAbstract | ||
| 59 | Affordability And Pricing Disclosure [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:AffordabilityAndPricingDisclosureTextBlock | |
| 60 | HC-BP-240b.1 [Abstract] | Abstract | sasb:HCBP240b1Abstract | ||
| 61 | Settlements Of Abbreviated New Drug Application Litigation That Involved Payments And Provisions To Delay Bringing An Authorized Generic Product To Market | Concept (xbrli:nonNegativeIntegerItemType) | For Period | sasb:SettlementsOfAbbreviatedNewDrugApplicationLitigationThatInvolvedPaymentsAndProvisionsToDelayBringingAnAuthorizedGenericProductToMarket | |
| 62 | HC-BP-240b.2 [Abstract] | Abstract | sasb:HCBP240b2Abstract | ||
| 63 | Average List Price Across Product Portfolio, Percentage Change Compared To Previous Year [Table] | Hypercube | sasb:AverageListPriceAcrossProductPortfolioPercentageChangeComparedToPreviousYearTable | ||
| 64 | Geographical [Axis] | Dimension | srt:StatementGeographicalAxis | ||
| 65 | Geographical [Domain] | Member | srt:SegmentGeographicalDomain | ||
| 66 | Africa [Member] | Member | srt:AfricaMember | ||
| 67 | Americas [Member] | Member | srt:AmericasMember | ||
| 68 | Asia [Member] | Member | srt:AsiaMember | ||
| 69 | Asia Pacific [Member] | Member | srt:AsiaPacificMember | ||
| 70 | Central America [Member] | Member | srt:CentralAmericaMember | ||
| 71 | Europe [Member] | Member | srt:EuropeMember | ||
| 72 | Latin America [Member] | Member | srt:LatinAmericaMember | ||
| 73 | North America [Member] | Member | srt:NorthAmericaMember | ||
| 74 | South America [Member] | Member | srt:SouthAmericaMember | ||
| 75 | UNITED STATES | Abstract | country:US | ||
| 76 | Average List Price Across Product Portfolio, Percentage Change Compared To Previous Year [Line Items] | LineItems | sasb:AverageListPriceAcrossProductPortfolioPercentageChangeComparedToPreviousYearLineItems | ||
| 77 | Average List Price Across Product Portfolio, Percentage Change Compared To Previous Year | Concept (dtr-types:percentItemType) | For Period | sasb:AverageListPriceAcrossProductPortfolioPercentageChangeComparedToPreviousYear | |
| 78 | Average Net Price Across Product Portfolio, Percentage Change Compared To Previous Year [Table] | Hypercube | sasb:AverageNetPriceAcrossProductPortfolioPercentageChangeComparedToPreviousYearTable | ||
| 79 | Geographical [Axis] | Dimension | srt:StatementGeographicalAxis | ||
| 80 | Geographical [Domain] | Member | srt:SegmentGeographicalDomain | ||
| 81 | Africa [Member] | Member | srt:AfricaMember | ||
| 82 | Americas [Member] | Member | srt:AmericasMember | ||
| 83 | Asia [Member] | Member | srt:AsiaMember | ||
| 84 | Asia Pacific [Member] | Member | srt:AsiaPacificMember | ||
| 85 | Central America [Member] | Member | srt:CentralAmericaMember | ||
| 86 | Europe [Member] | Member | srt:EuropeMember | ||
| 87 | Latin America [Member] | Member | srt:LatinAmericaMember | ||
| 88 | North America [Member] | Member | srt:NorthAmericaMember | ||
| 89 | South America [Member] | Member | srt:SouthAmericaMember | ||
| 90 | UNITED STATES | Abstract | country:US | ||
| 91 | Average Net Price Across Product Portfolio, Percentage Change Compared To Previous Year [Line Items] | LineItems | sasb:AverageNetPriceAcrossProductPortfolioPercentageChangeComparedToPreviousYearLineItems | ||
| 92 | Average Net Price Across Product Portfolio, Percentage Change Compared To Previous Year | Concept (dtr-types:percentItemType) | For Period | sasb:AverageNetPriceAcrossProductPortfolioPercentageChangeComparedToPreviousYear | |
| 93 | HC-BP-240b.3 [Abstract] | Abstract | sasb:HCBP240b3Abstract | ||
| 94 | List Price Of Product With Largest Increase, Percentage Change Compared To Previous Year | Concept (dtr-types:percentItemType) | For Period | sasb:ListPriceOfProductWithLargestIncreasePercentageChangeComparedToPreviousYear | |
| 95 | Net Price Of Product With Largest Increase, Percentage Change Compared To Previous Year | Concept (dtr-types:percentItemType) | For Period | sasb:NetPriceOfProductWithLargestIncreasePercentageChangeComparedToPreviousYear | |
| 96 | Drug Safety Disclosure [Abstract] | Abstract | sasb:DrugSafetyDisclosureAbstract | ||
| 97 | Drug Safety Disclosure [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:DrugSafetyDisclosureTextBlock | |
| 98 | HC-BP-250a.1 [Abstract] | Abstract | sasb:HCBP250a1Abstract | ||
| 99 | Products Listed In FDA Medwatch Safety Alerts For Human Medical Products Database [Table] | Hypercube | sasb:ProductsListedInFDAMedwatchSafetyAlertsForHumanMedicalProductsDatabaseTable | ||
| 100 | Medical Products [Axis] | Dimension | sasb:MedicalProductsAxis | ||
| 101 | Medical Products [Domain] | Abstract | sasb:MedicalProductsDomain | ||
| 102 | Products Listed In FDA Medwatch Safety Alerts For Human Medical Products Database [Line Items] | LineItems | sasb:ProductsListedInFDAMedwatchSafetyAlertsForHumanMedicalProductsDatabaseLineItems | ||
| 103 | Products Listed In FDA Medwatch Safety Alerts For Human Medical Products Database | Concept (enum2:enumerationSetItemType) | For Period | sasb:ProductsListedInFDAMedwatchSafetyAlertsForHumanMedicalProductsDatabase | |
| 104 | HC-BP-250a.2 [Abstract] | Abstract | sasb:HCBP250a2Abstract | ||
| 105 | Fatalities, Number Associated With Products As Reported In FDA Adverse Event Reporting System | Concept (xbrli:nonNegativeIntegerItemType) | For Period | sasb:FatalitiesNumberAssociatedWithProductsAsReportedInFDAAdverseEventReportingSystem | |
| 106 | HC-BP-250a.3 [Abstract] | Abstract | sasb:HCBP250a3Abstract | ||
| 107 | Product Recalls | Concept (xbrli:nonNegativeIntegerItemType) | For Period | sasb:ProductRecalls | |
| 108 | Product Recalls, Units | Concept (xbrli:nonNegativeIntegerItemType) | For Period | sasb:ProductRecallsUnits | |
| 109 | Notable Recalls, Discussion [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:NotableRecallsDiscussionTextBlock | |
| 110 | HC-BP-250a.4 [Abstract] | Abstract | sasb:HCBP250a4Abstract | ||
| 111 | Product Accepted For Take-back, Reuse, Or Disposal | Concept (dtr-types:massItemType) | For Period | sasb:ProductAcceptedForTakeBackReuseOrDisposal | |
| 112 | HC-BP-250a.5 [Abstract] | Abstract | sasb:HCBP250a5Abstract | ||
| 113 | FDA Enforcement Actions Taken In Response To Violations Of Current Good Manufacturing Practices [Table] | Hypercube | sasb:FDAEnforcementActionsTakenInResponseToViolationsOfCurrentGoodManufacturingPracticesTable | ||
| 114 | FDA Enforcement Action [Axis] | Dimension | sasb:FDAEnforcementActionAxis | ||
| 115 | FDA Enforcement Action [Domain] | Abstract | sasb:FDAEnforcementActionDomain | ||
| 116 | Consent Decrees [Member] | Abstract | sasb:ConsentDecreesMember | ||
| 117 | Form 483s [Member] | Abstract | sasb:Form483sMember | ||
| 118 | Recalls [Member] | Abstract | sasb:RecallsMember | ||
| 119 | Seizures [Member] | Abstract | sasb:SeizuresMember | ||
| 120 | Warning Letters [Member] | Abstract | sasb:WarningLettersMember | ||
| 121 | FDA Enforcement Actions Taken In Response To Violations Of Current Good Manufacturing Practices [Line Items] | LineItems | sasb:FDAEnforcementActionsTakenInResponseToViolationsOfCurrentGoodManufacturingPracticesLineItems | ||
| 122 | FDA Enforcement Actions Taken In Response To Violations Of Current Good Manufacturing Practices | Concept (xbrli:nonNegativeIntegerItemType) | For Period | sasb:FDAEnforcementActionsTakenInResponseToViolationsOfCurrentGoodManufacturingPractices | |
| 123 | Counterfeit Drugs Disclosure [Abstract] | Abstract | sasb:CounterfeitDrugsDisclosureAbstract | ||
| 124 | Counterfeit Drugs Disclosure [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:CounterfeitDrugsDisclosureTextBlock | |
| 125 | HC-BP-260a.1 [Abstract] | Abstract | sasb:HCBP260a1Abstract | ||
| 126 | Methods And Technologies Used To Maintain Traceability Of Products Throughout Distribution Chain [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:MethodsAndTechnologiesUsedToMaintainTraceabilityOfProductsThroughoutDistributionChainTextBlock | |
| 127 | HC-BP-260a.2 [Abstract] | Abstract | sasb:HCBP260a2Abstract | ||
| 128 | Counterfeit Products, Process For Alerting Customers And Business Partners Of Potential Or Known Risks [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:CounterfeitProductsProcessForAlertingCustomersAndBusinessPartnersOfPotentialOrKnownRisksTextBlock | |
| 129 | HC-BP-260a.3 [Abstract] | Abstract | sasb:HCBP260a3Abstract | ||
| 130 | Counterfeit Products, Actions That Led To Raids, Seizure, Arrests, And Filing Of Criminal Charges | Concept (xbrli:nonNegativeIntegerItemType) | For Period | sasb:CounterfeitProductsActionsThatLedToRaidsSeizureArrestsAndFilingOfCriminalCharges | |
| 131 | Counterfeit Products, Description Of Actions That Led To Raids, Seizure, Arrests, And Filing Of Criminal Charges [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:CounterfeitProductsDescriptionOfActionsThatLedToRaidsSeizureArrestsAndFilingOfCriminalChargesTextBlock | |
| 132 | Ethical Marketing Disclosure [Abstract] | Abstract | sasb:EthicalMarketingDisclosureAbstract | ||
| 133 | Ethical Marketing Disclosure [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:EthicalMarketingDisclosureTextBlock | |
| 134 | HC-BP-270a.1 [Abstract] | Abstract | sasb:HCBP270a1Abstract | ||
| 135 | Losses As Result Of Legal Proceedings [Table] | Hypercube | sasb:LossesAsResultOfLegalProceedingsTable | ||
| 136 | Legal Proceeding Association [Axis] | Dimension | sasb:LegalProceedingAssociationAxis | ||
| 137 | Legal Proceeding Association [Domain] | Abstract | sasb:LegalProceedingAssociationDomain | ||
| 138 | Bribery Or Corruption [Member] | Abstract | sasb:BriberyOrCorruptionMember | ||
| 139 | Clinical Trials In Developing Countries [Member] | Abstract | sasb:ClinicalTrialsInDevelopingCountriesMember | ||
| 140 | False Marketing Claims [Member] | Abstract | sasb:FalseMarketingClaimsMember | ||
| 141 | Losses As Result Of Legal Proceedings [Line Items] | LineItems | sasb:LossesAsResultOfLegalProceedingsLineItems | ||
| 142 | Losses As Result Of Legal Proceedings | Concept (Monetary) | For Period | sasb:LossesAsResultOfLegalProceedings | |
| 143 | Nature, Context, And Corrective Actions Taken As Result Of Monetary Losses From Legal Proceedings [Text Block] [Table] | Hypercube | sasb:NatureContextAndCorrectiveActionsTakenAsResultOfMonetaryLossesFromLegalProceedingsTextBlockTable | ||
| 144 | Legal Proceeding Association [Axis] | Dimension | sasb:LegalProceedingAssociationAxis | ||
| 145 | Legal Proceeding Association [Domain] | Abstract | sasb:LegalProceedingAssociationDomain | ||
| 146 | Bribery Or Corruption [Member] | Abstract | sasb:BriberyOrCorruptionMember | ||
| 147 | Clinical Trials In Developing Countries [Member] | Abstract | sasb:ClinicalTrialsInDevelopingCountriesMember | ||
| 148 | False Marketing Claims [Member] | Abstract | sasb:FalseMarketingClaimsMember | ||
| 149 | Nature, Context, And Corrective Actions Taken As Result Of Monetary Losses From Legal Proceedings [Text Block] [Line Items] | LineItems | sasb:NatureContextAndCorrectiveActionsTakenAsResultOfMonetaryLossesFromLegalProceedingsTextBlockLineItems | ||
| 150 | Nature, Context, And Corrective Actions Taken As Result Of Monetary Losses From Legal Proceedings [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:NatureContextAndCorrectiveActionsTakenAsResultOfMonetaryLossesFromLegalProceedingsTextBlock | |
| 151 | HC-BP-270a.2 [Abstract] | Abstract | sasb:HCBP270a2Abstract | ||
| 152 | Code Of Ethics Governing Promotion Of Off-label Use Of Products [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:CodeOfEthicsGoverningPromotionOfOffLabelUseOfProductsTextBlock | |
| 153 | Employee Recruitment, Development And Retention Disclosure [Abstract] | Abstract | sasb:EmployeeRecruitmentDevelopmentAndRetentionDisclosureAbstract | ||
| 154 | Employee Recruitment, Development And Retention Disclosure [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:EmployeeRecruitmentDevelopmentAndRetentionDisclosureTextBlock | |
| 155 | HC-BP-330a.1 [Abstract] | Abstract | sasb:HCBP330a1Abstract | ||
| 156 | Talent Recruitment And Retention Efforts For Scientists And Research And Development Personnel [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:TalentRecruitmentAndRetentionEffortsForScientistsAndResearchAndDevelopmentPersonnelTextBlock | |
| 157 | HC-BP-330a.2 [Abstract] | Abstract | sasb:HCBP330a2Abstract | ||
| 158 | Employee Turnover Rate, Involuntary [Table] | Hypercube | sasb:EmployeeTurnoverRateInvoluntaryTable | ||
| 159 | Employee By Position Type [Axis] | Dimension | sasb:EmployeeByPositionTypeAxis | ||
| 160 | Employee By Position Type [Domain] | Abstract | sasb:EmployeeByPositionTypeDomain | ||
| 161 | Executives/Senior Managers [Member] | Abstract | sasb:ExecutivesSeniorManagersMember | ||
| 162 | Mid-level Managers [Member] | Abstract | sasb:MidlevelManagersMember | ||
| 163 | Employee By Profession Type [Axis] | Dimension | sasb:EmployeeByProfessionTypeAxis | ||
| 164 | Employee By Profession Type [Domain] | Abstract | sasb:EmployeeByProfessionTypeDomain | ||
| 165 | All Other, EEO-1 Categories; Technicians, Sales, Admin Support, Service Workers [Member] | Abstract | sasb:AllOtherEEO1CategoriesTechniciansSalesAdminSupportServiceWorkersMember | ||
| 166 | Healthcare Professionals [Member] | Abstract | sasb:HealthcareProfessionalsMember | ||
| 167 | Employee Turnover Rate, Involuntary [Line Items] | LineItems | sasb:EmployeeTurnoverRateInvoluntaryLineItems | ||
| 168 | Employee Turnover Rate, Involuntary | Concept (Pure) | For Period | sasb:EmployeeTurnoverRateInvoluntary | |
| 169 | Employee Turnover Rate, Voluntary [Table] | Hypercube | sasb:EmployeeTurnoverRateVoluntaryTable | ||
| 170 | Employee By Position Type [Axis] | Dimension | sasb:EmployeeByPositionTypeAxis | ||
| 171 | Employee By Position Type [Domain] | Abstract | sasb:EmployeeByPositionTypeDomain | ||
| 172 | Executives/Senior Managers [Member] | Abstract | sasb:ExecutivesSeniorManagersMember | ||
| 173 | Mid-level Managers [Member] | Abstract | sasb:MidlevelManagersMember | ||
| 174 | Employee By Profession Type [Axis] | Dimension | sasb:EmployeeByProfessionTypeAxis | ||
| 175 | Employee By Profession Type [Domain] | Abstract | sasb:EmployeeByProfessionTypeDomain | ||
| 176 | All Other, EEO-1 Categories; Technicians, Sales, Admin Support, Service Workers [Member] | Abstract | sasb:AllOtherEEO1CategoriesTechniciansSalesAdminSupportServiceWorkersMember | ||
| 177 | Healthcare Professionals [Member] | Abstract | sasb:HealthcareProfessionalsMember | ||
| 178 | Employee Turnover Rate, Voluntary [Line Items] | LineItems | sasb:EmployeeTurnoverRateVoluntaryLineItems | ||
| 179 | Employee Turnover Rate, Voluntary | Concept (Pure) | For Period | sasb:EmployeeTurnoverRateVoluntary | |
| 180 | Supply Chain Management Disclosure [Abstract] | Abstract | sasb:SupplyChainManagementDisclosureAbstract | ||
| 181 | Supply Chain Management Disclosure [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:SupplyChainManagementDisclosureTextBlock | |
| 182 | HC-BP-430a.1 [Abstract] | Abstract | sasb:HCBP430a1Abstract | ||
| 183 | Supplier Facilities, Percentage Participating In Pharmaceutical Supply Chain Consortium Audit Program [Table] | Hypercube | sasb:SupplierFacilitiesPercentageParticipatingInPharmaceuticalSupplyChainConsortiumAuditProgramTable | ||
| 184 | Supplier Tier [Axis] | Dimension | sasb:SupplierTierAxis | ||
| 185 | Supplier Tier [Domain] | Abstract | sasb:SupplierTierDomain | ||
| 186 | Tier 1 Supplier [Member] | Abstract | sasb:Tier1SupplierMember | ||
| 187 | Supplier Facilities, Percentage Participating In Pharmaceutical Supply Chain Consortium Audit Program [Line Items] | LineItems | sasb:SupplierFacilitiesPercentageParticipatingInPharmaceuticalSupplyChainConsortiumAuditProgramLineItems | ||
| 188 | Supplier Facilities, Percentage Participating In Pharmaceutical Supply Chain Consortium Audit Program | Concept (dtr-types:percentItemType) | For Period | sasb:SupplierFacilitiesPercentageParticipatingInPharmaceuticalSupplyChainConsortiumAuditProgram | |
| 189 | Entity Facilities, Percentage Participating In Pharmaceutical Supply Chain Consortium Audit Program | Concept (dtr-types:percentItemType) | For Period | sasb:EntityFacilitiesPercentageParticipatingInPharmaceuticalSupplyChainConsortiumAuditProgram | |
| 190 | Business Ethics Disclosure [Abstract] | Abstract | sasb:BusinessEthicsDisclosureAbstract | ||
| 191 | Business Ethics Disclosure [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:BusinessEthicsDisclosureTextBlock | |
| 192 | HC-BP-510a.1 [Abstract] | Abstract | sasb:HCBP510a1Abstract | ||
| 193 | Losses As Result Of Legal Proceedings [Table] | Hypercube | sasb:LossesAsResultOfLegalProceedingsTable | ||
| 194 | Legal Proceeding Association [Axis] | Dimension | sasb:LegalProceedingAssociationAxis | ||
| 195 | Legal Proceeding Association [Domain] | Abstract | sasb:LegalProceedingAssociationDomain | ||
| 196 | Bribery Or Corruption [Member] | Abstract | sasb:BriberyOrCorruptionMember | ||
| 197 | Clinical Trials In Developing Countries [Member] | Abstract | sasb:ClinicalTrialsInDevelopingCountriesMember | ||
| 198 | False Marketing Claims [Member] | Abstract | sasb:FalseMarketingClaimsMember | ||
| 199 | Losses As Result Of Legal Proceedings [Line Items] | LineItems | sasb:LossesAsResultOfLegalProceedingsLineItems | ||
| 200 | Losses As Result Of Legal Proceedings | Concept (Monetary) | For Period | sasb:LossesAsResultOfLegalProceedings | |
| 201 | Nature, Context, And Corrective Actions Taken As Result Of Monetary Losses From Legal Proceedings [Text Block] [Table] | Hypercube | sasb:NatureContextAndCorrectiveActionsTakenAsResultOfMonetaryLossesFromLegalProceedingsTextBlockTable | ||
| 202 | Legal Proceeding Association [Axis] | Dimension | sasb:LegalProceedingAssociationAxis | ||
| 203 | Legal Proceeding Association [Domain] | Abstract | sasb:LegalProceedingAssociationDomain | ||
| 204 | Bribery Or Corruption [Member] | Abstract | sasb:BriberyOrCorruptionMember | ||
| 205 | Clinical Trials In Developing Countries [Member] | Abstract | sasb:ClinicalTrialsInDevelopingCountriesMember | ||
| 206 | False Marketing Claims [Member] | Abstract | sasb:FalseMarketingClaimsMember | ||
| 207 | Nature, Context, And Corrective Actions Taken As Result Of Monetary Losses From Legal Proceedings [Text Block] [Line Items] | LineItems | sasb:NatureContextAndCorrectiveActionsTakenAsResultOfMonetaryLossesFromLegalProceedingsTextBlockLineItems | ||
| 208 | Nature, Context, And Corrective Actions Taken As Result Of Monetary Losses From Legal Proceedings [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:NatureContextAndCorrectiveActionsTakenAsResultOfMonetaryLossesFromLegalProceedingsTextBlock | |
| 209 | HC-BP-510a.2 [Abstract] | Abstract | sasb:HCBP510a2Abstract | ||
| 210 | Code Of Ethics Governing Interactions With Health Care Professionals [Text Block] | Concept (dtr-types:textBlockItemType) | For Period | sasb:CodeOfEthicsGoverningInteractionsWithHealthCareProfessionalsTextBlock | |
| 211 | Biotechnology And Pharmaceuticals Industry, Activity Metrics [Abstract] | Abstract | sasb:BiotechnologyAndPharmaceuticalsIndustryActivityMetricsAbstract | ||
| 212 | HC-BP-000.A [Abstract] | Abstract | sasb:HCBP000AAbstract | ||
| 213 | Patients Treated, Number | Concept (xbrli:nonNegativeIntegerItemType) | For Period | sasb:PatientsTreatedNumber | |
| 214 | HC-BP-000.B [Abstract] | Abstract | sasb:HCBP000BAbstract | ||
| 215 | Drugs In Portfolio, Number | Concept (xbrli:nonNegativeIntegerItemType) | As Of | sasb:DrugsInPortfolioNumber | |
| 216 | Drugs In Research And Development, Number | Concept (xbrli:nonNegativeIntegerItemType) | As Of | sasb:DrugsInResearchAndDevelopmentNumber |
Last updated: 7/30/2021 7:21:18 AM